BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 19744286)

  • 1. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
    Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.
    Widmann T; Sester U; Gärtner BC; Schubert J; Pfreundschuh M; Köhler H; Sester M
    PLoS One; 2008; 3(11):e3634. PubMed ID: 18982061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
    Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
    Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
    Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
    Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
    Fleming T; Dunne J; Crowley B
    J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
    Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
    Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara.
    La Rosa C; Wang Z; Lacey SF; Lalimarmo MM; Krishnan A; Longmate J; Diamond DJ
    Exp Hematol; 2006 Apr; 34(4):497-507. PubMed ID: 16569596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.
    Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; López J; Garcia-Noblejas A; Muñoz-Cobo B; Costa E; Clari MA; Hernández-Boluda JC; Remigia MJ; Navarro D
    Bone Marrow Transplant; 2011 Nov; 46(11):1437-43. PubMed ID: 21243030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
    Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.
    Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; Garcia-Noblejas A; Clari MA; Chilet M; López J; Hernández-Boluda JC; Remigia MJ; Navarro D
    J Med Virol; 2010 Jul; 82(7):1208-15. PubMed ID: 20513086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immune parameters associated with spontaneous control of CMV in children who underwent transplantation.
    Guérin V; Dalle JH; Pédron B; Ouachée-Chardin M; Yakouben K; Baruchel A; Sterkers G
    Bone Marrow Transplant; 2010 Mar; 45(3):442-9. PubMed ID: 19633694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
    Avetisyan G; Larsson K; Aschan J; Nilsson C; Hassan M; Ljungman P
    Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection.
    Eid AJ; Brown RA; Arthurs SK; Lahr BD; Eckel-Passow JE; Larson TS; Razonable RR
    Transpl Int; 2010 May; 23(5):506-13. PubMed ID: 19951371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
    Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.
    Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L
    Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT.
    Król L; Stuchlý J; Hubáček P; Keslová P; Sedláček P; Starý J; Hrušák O; Kalina T
    Bone Marrow Transplant; 2011 Aug; 46(8):1089-98. PubMed ID: 21057553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.